Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
An Open-label, Multicentre, Phase II Study to Evaluate the Safety and Efficacy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
Terminated
Internal strategy change. Not related to safety concerns.
Other terminated trials from CSPC Ouyi Pharmaceutical Co., Ltd.
More terminations from CSPC Ouyi Pharmaceutical Co., Ltd.
A PHASE2 clinical study on Advanced Biliary Tract Cancer and Extrahepatic Cholangiocarcinoma, this trial is terminated or withdrawn. The trial is conducted by CSPC Ouyi Pharmaceutical Co., Ltd. and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE2
Status: Not Yet Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CSPC Ouyi Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .